OCUL
Neutral signalScored 2026-10-20 Drivers: trend, fundamentals. Insiders: neutral. Moteurs : tendance, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Ocular Therapeutix, Inc.
- Nom
- Ocular Therapeutix, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $1.4B
- Employés
- 325
- PDG
- Pravin U. Dugel
- Site web
- https://www.ocutx.com
- Marché
- BLCOEYPTGKOSHROWKODOCGN
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 21 649 titres (~233 159,73 $ US)
- Insiders
- Dugel Pravin
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$567,500
Avg sell (VWAP, 90d window) $8.89 vs last close $6.29 (-29.3%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$556,247 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-08-24
- Liquidity
- Liquid $26,476,047/day · 20d vol
- Last synced
-
2026-10-20 02:38:31
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-08 | Anderman Todd | Sell · S · 10b5-1 | 11,984 | $7.29 | $87,363 | Form 4 |
| 2026-10-02 | Heier Jeffrey S. | Sell · S · 10b5-1 | 10,869 | $7.05 | $76,626 | Form 4 |
| 2026-10-02 | Kaiser Peter | Sell · S · 10b5-1 | 9,990 | $7.05 | $70,430 | Form 4 |
| 2026-08-31 | Notman Donald | Sell · S | 1,099 | $10.24 | $11,254 | Form 4 |
| 2026-08-24 | Dugel Pravin | Sell · S · 10b5-1 | 21,649 | $10.77 | $233,160 | Form 4 |
| 2026-08-24 | Heier Jeffrey S. | Sell · S · 10b5-1 | 3,296 | $10.78 | $35,531 | Form 4 |
| 2026-08-24 | Kaiser Peter | Sell · S · 10b5-1 | 3,035 | $10.77 | $32,687 | Form 4 |
| 2026-08-24 | Nayak Sanjay | Sell · S · 10b5-1 | 1,897 | $10.78 | $20,450 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-10-20 Drivers: trend, fundamentals. Insiders: neutral. Moteurs : tendance, fondamentaux. Initiés : neutre.
OCUL presents a high-conviction regulatory catalyst — a confirmed Q4 NDA submission for AXPAXLI in wet AMD following a positive pre-NDA FDA meeting — that meaningfully offsets its severe financial distress.
The first sentence of the analysis written for OCUL on 2026-10-20 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $322K) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $322K) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Unavailable or mixed. Current ratio 15.39 · operating margin -521% — readings disagree
Suggested stop 6.00, nearest stored support minus 0.5 ATR(4.7% under the last close). Reward/risk to the next stored resistance is 8.50. Research, not advice. Not an order.
Recent news
- 2026-10-09 Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to fifteen newly hired non-executive employees. The awards were made as an inducement material to each recipient''s acceptance of employment with Ocular under Ocular''s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
- 2026-10-01 Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences BEDFORD, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in October 2026.
- 2026-09-22 Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Success Ocular Therapeutix NASDAQ: OCUL said it remains on track to submit a U.S. marketing application for AXPAXLI in the fourth quarter of this year, following what Chief Executive Officer Pravin Dugel described as alignment with the Food and Drug Administration on the company''s planned submission package for wet age-related macular degeneration, or wet AMD.
- 2026-09-18 Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to nine newly hired non-executive employees. The awards were made as an inducement material to each recipient''s acceptance of employment with Ocular under Ocular''s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
- 2026-09-15 Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD Consistent with prior Type C Meeting, the Pre-NDA Meeting confirms Ocular''s plan to submit AXPAXLI NDA based on SOL-1 Week 52 efficacy and safety, interim SOL-R safety, and confirmatory evidence AXPAXLI NDA submission for wet AMD remains on track for 4Q 2026 NDA submission to include subjects that have received multiple AXPAXLI injections in support of the Company''s application for repeat dosing Commercial readiness accelerates ahead of potential 2027 launch as AXPAXLI is well positioned to potentially be the first TKI approved for wet AMD BEDFORD, Mass., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced the successful completion of its Pre-New Drug Application (NDA) Meeting with the U.S. Food and Drug Administration (FDA) for its investigational product candidate AXPAXLI™ (also known as OTX-TKI) for the treatment of wet age-related macular degeneration (wet AMD).
- 2026-09-01 Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences BEDFORD, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in September and October 2026.
- 2026-08-28 BlackRock Inc. Invests $190.28 Million in Ocular Therapeutix, Inc. $OCUL BlackRock Inc. purchased a new stake in Ocular Therapeutix, Inc. (NASDAQ: OCUL) in the undefined quarter, according to its most recent disclosure with the SEC. The fund purchased 19,376,555 shares of the biopharmaceutical company''s stock, valued at approximately $190,278,000. BlackRock Inc. owned 8.82% of Ocular Therapeutix as of its most recent filing with
- 2026-08-18 Ocular Therapeutix, Inc. (OCUL) Discusses Regulatory Progress and NDA Filing Plans for AXPAXLI Transcript Ocular Therapeutix, Inc. (OCUL) Discusses Regulatory Progress and NDA Filing Plans for AXPAXLI Transcript
- 2026-08-17 Why Is Ocular Therapeutix Stock Gaining Monday? Ocular Therapeutix Inc. (NASDAQ:OCUL) stock is trading higher on Monday as the stock reacts to underwhelming data from its rival, EyePoint Inc. (NASDAQ:EYPT).
- 2026-08-13 Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to Ms. Beth Rada, the Company''s new SVP, Government Affairs and Public Policy. The awards were made as an inducement material to the recipient''s acceptance of employment with Ocular under Ocular''s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 87.3% | 91.2% | 91.0% | 91.2% | 89.9% | |
| Ebit Margin | -490.3% | -282.4% | -118.7% | -124.3% | 0.3% | |
| Ebitda Margin | -482.0% | -276.4% | -113.6% | -120.2% | 5.8% | |
| Operating Profit Margin | -521.0% | -269.6% | -141.0% | -152.7% | -179.3% | |
| Pretax Profit Margin | -513.2% | -303.7% | -138.1% | -138.0% | -15.1% | |
| Continuous Operations Profit Margin | -513.2% | -303.7% | -138.1% | -138.0% | -15.1% | |
| Net Profit Margin | -513.2% | -303.7% | -138.1% | -138.0% | -15.1% | |
| Bottom Line Profit Margin | -513.2% | -303.7% | -148.8% | -155.9% | -184.4% | |
| Current Ratio | 15.394 | 10.664 | 6.655 | 4.129 | 7.264 | |
| Quick Ratio | 15.324 | 10.590 | 6.589 | 4.066 | 7.216 | |
| Solvency Ratio | -1.702 | -1.331 | -0.483 | -0.605 | -0.035 | |
| Cash Ratio | 14.507 | 9.482 | 5.611 | 3.258 | 6.233 | |
| Price To Earnings Ratio | -8.549 | -7.000 | -4.092 | -2.702 | -6.638 | |
| Price To Earnings Growth Ratio | -0.522 | -0.587 | -0.851 | 2.837 | 0.113 | |
| Forward Price To Earnings Growth Ratio | -0.522 | -0.587 | -0.851 | 2.837 | 0.113 | |
| Price To Earnings Diluted Ratio | -8.549 | -7.000 | -4.373 | -2.897 | -7.112 | |
| Price To Earnings Diluted Growth Ratio | -0.522 | -0.357 | -0.848 | 2.839 | 0.115 | |
| Price To Book Ratio | 3.474 | 4.286 | 3.907 | 6.106 | 6.051 | |
| Price To Sales Ratio | 43.863 | 21.210 | 6.092 | 4.195 | 12.234 | |
| Price To Free Cash Flow Ratio | -10.480 | -9.941 | -4.665 | -3.412 | -7.978 | |
| Price To Operating Cash Flow Ratio | -11.095 | -10.036 | -5.069 | -3.624 | -8.123 | |
| Debt To Assets Ratio | 0.099 | 0.165 | 0.331 | 0.431 | 0.288 | |
| Debt To Equity Ratio | 0.122 | 0.240 | 0.915 | 1.817 | 0.670 | |
| Debt To Capital Ratio | 0.109 | 0.194 | 0.478 | 0.645 | 0.401 | |
| Long Term Debt To Capital Ratio | 0.102 | 0.178 | 0.451 | 0.604 | 0.369 | |
| Financial Leverage Ratio | 1.235 | 1.452 | 2.766 | 4.220 | 2.328 | |
| Working Capital Turnover Ratio | 0.092 | 0.213 | 0.395 | 0.391 | 0.226 | |
| Operating Cash Flow Ratio | -4.033 | -3.257 | -2.013 | -1.898 | -2.489 | |
| Operating Cash Flow Sales Ratio | -3.954 | -2.113 | -1.202 | -1.157 | -1.506 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.059 | 1.010 | 1.087 | 1.062 | 1.018 | |
| Debt Service Coverage Ratio | -17.048 | -12.974 | -5.858 | -8.816 | 0.381 | |
| Interest Coverage Ratio | -22.815 | -12.652 | -7.266 | -11.201 | -11.698 | |
| Short Term Operating Cash Flow Coverage Ratio | -72.731 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -2.568 | -1.777 | -0.842 | -0.927 | -1.111 | |
| Capital Expenditure Coverage Ratio | -17.059 | -104.563 | -11.538 | -16.044 | -54.899 | |
| Dividend Paid And Capex Coverage Ratio | -17.059 | -104.563 | -11.538 | -16.044 | -54.899 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -6.469 | -5.877 | -3.668 | -2.875 | 168.286 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 87.3% | ▼-3.9% | ▼-2.8% |
| Ebit Margin | -490.3% | ▼-208.0% | ▼-287.2% |
| Ebitda Margin | -482.0% | ▼-205.6% | ▼-284.7% |
| Operating Profit Margin | -521.0% | ▼-251.5% | ▼-268.3% |
| Pretax Profit Margin | -513.2% | ▼-209.5% | ▼-291.6% |
| Continuous Operations Profit Margin | -513.2% | ▼-209.5% | ▼-291.6% |
| Net Profit Margin | -513.2% | ▼-209.5% | ▼-291.6% |
| Bottom Line Profit Margin | -513.2% | ▼-209.5% | ▼-252.0% |
| Current Ratio | 15.394 | ▲4.731 | ▲6.573 |
| Quick Ratio | 15.324 | ▲4.734 | ▲6.567 |
| Solvency Ratio | -1.702 | ▼-0.371 | ▼-0.871 |
| Cash Ratio | 14.507 | ▲5.026 | ▲6.689 |
| Price To Earnings Ratio | -8.549 | ▼-1.549 | ▼-2.753 |
| Price To Earnings Growth Ratio | -0.521 | ▲0.065 | ▼-0.720 |
| Forward Price To Earnings Growth Ratio | -0.521 | ▲0.065 | ▼-0.720 |
| Price To Earnings Diluted Ratio | -8.549 | ▼-1.549 | ▼-2.563 |
| Price To Earnings Diluted Growth Ratio | -0.521 | ▼-0.165 | ▼-0.767 |
| Price To Book Ratio | 3.474 | ▼-0.812 | ▼-1.291 |
| Price To Sales Ratio | 43.863 | ▲22.653 | ▲26.344 |
| Price To Free Cash Flow Ratio | -10.480 | ▼-0.540 | ▼-3.185 |
| Price To Operating Cash Flow Ratio | -11.095 | ▼-1.059 | ▼-3.505 |
| Debt To Assets Ratio | 0.099 | ▼-0.067 | ▼-0.164 |
| Debt To Equity Ratio | 0.122 | ▼-0.118 | ▼-0.631 |
| Debt To Capital Ratio | 0.109 | ▼-0.085 | ▼-0.257 |
| Long Term Debt To Capital Ratio | 0.102 | ▼-0.077 | ▼-0.239 |
| Financial Leverage Ratio | 1.235 | ▼-0.217 | ▼-1.165 |
| Working Capital Turnover Ratio | 0.092 | ▼-0.122 | ▼-0.172 |
| Operating Cash Flow Ratio | -4.033 | ▼-0.776 | ▼-1.295 |
| Operating Cash Flow Sales Ratio | -3.954 | ▼-1.840 | ▼-1.967 |
| Free Cash Flow Operating Cash Flow Ratio | 1.059 | ▲0.049 | ▲0.011 |
| Debt Service Coverage Ratio | -17.048 | ▼-4.074 | ▼-8.185 |
| Interest Coverage Ratio | -22.815 | ▼-10.163 | ▼-9.689 |
| Short Term Operating Cash Flow Coverage Ratio | -72.731 | ▼-72.731 | ▼-58.185 |
| Operating Cash Flow Coverage Ratio | -2.568 | ▼-0.791 | ▼-1.123 |
| Capital Expenditure Coverage Ratio | -17.059 | ▲87.504 | ▲23.761 |
| Dividend Paid And Capex Coverage Ratio | -17.059 | ▲87.504 | ▲23.761 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -6.469 | ▼-0.592 | ▼-36.348 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $2.27B | $1.35B | $356.0M | $216.0M | $532.5M | |
| Enterprise value | $1.62B | $1.04B | $243.6M | $178.0M | $427.3M | |
| EV / Sales | 31.18x | 16.25x | 4.17x | 3.46x | 9.82x | |
| EV / Op. cash flow | -7.89x | -7.69x | -3.47x | -2.99x | -6.52x | |
| EV / Free cash flow | -7.45x | -7.61x | -3.19x | -2.81x | -6.40x | |
| EV / EBITDA | -6.47x | -5.88x | -3.67x | -2.88x | 168.29x | |
| Net debt / EBITDA | 2.63x | 1.80x | 1.69x | 0.61x | -41.43x | |
| Current ratio | 15.39x | 10.66x | 6.66x | 4.13x | 7.26x | |
| Income quality | 0.77x | 0.70x | 0.87x | 0.84x | 10.00x | |
| Graham net-net | $3 | $2 | $1 | $0 | $1 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 104.7% | 107.5% | 116.3% | 111.0% | -5553.4% | |
| Working capital | $731.3M | $399.6M | $197.3M | $98.2M | $165.0M | |
| Invested capital | $755.6M | $415.0M | $215.6M | $116.1M | $176.8M | |
| Return on assets | -32.9% | -42.3% | -32.0% | -47.6% | -3.2% | |
| Operating ROA | -42.7% | -48.4% | -41.1% | -44.4% | -33.4% | |
| Return on tangible assets | -32.9% | -42.3% | -32.0% | -47.6% | -3.2% | |
| Return on equity | -40.6% | -61.4% | -88.6% | -200.8% | -7.4% | |
| Return on invested capital | -35.5% | -41.0% | -37.7% | -65.8% | -43.3% | |
| Return on capital employed | -35.7% | -41.2% | -37.9% | -66.7% | -43.7% | |
| Earnings yield | -11.7% | -14.3% | -22.7% | -32.9% | -1.2% | |
| Free cash flow yield | -9.5% | -10.1% | -21.4% | -29.3% | -12.5% | |
| Capex / Op. cash flow | -5.9% | -1.0% | -8.7% | -6.2% | -1.8% | |
| Capex / Depreciation | 277.8% | 34.0% | 204.1% | 176.1% | 49.3% | |
| Capex / Sales | 23.2% | 2.0% | 10.4% | 7.2% | 2.7% | |
| SG&A / Sales | 228.3% | 160.4% | 127.5% | 140.1% | 154.1% | |
| R&D / Sales | 380.3% | 200.3% | 104.5% | 103.8% | 115.1% | |
| Stock comp / Sales | 83.3% | 52.0% | 30.5% | 32.9% | 34.4% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 216d | 186d | 163d | 151d | 177d | |
| Days payables outstanding | 231d | 271d | 303d | 412d | 380d | |
| Operating cycle | 414d | 383d | 323d | 310d | 281d | |
| Cash conversion cycle | 183d | 112d | 19d | -102d | -100d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years